Cenedella.de

Patient Advocate since 1977.


Leave a comment

CALIFORNIA BUREAU OF MEDICAL CANNABIS REGULATION – PROPOSED REGULATIONS FOR MEDICAL CANNABIS

BUREAU OF MEDICAL CANNABIS REGULATION RELEASES PROPOSED REGULATIONS FOR MEDICAL CANNABIS

The Bureau of Medical Cannabis Regulation (BMCR) today announced that its proposed licensing regulations for medical cannabis have been posted and the 45-day public comment period is now underway.

“The proposed licensing regulations for medical cannabis are the result of countless hours of research, stakeholder outreach, informational sessions and pre-regulatory meetings all across the state,” BMCR Chief Lori Ajax said. “And while we have done quite a bit of work and heard from thousands of people, there is still so much more to do. In order to make our program successful we still need your feedback.”

Individuals interested in reviewing the medical regulations for licensing dispensaries, distribution and transporters can do so by visiting the new Cannabis Web Portal, www.cannabis.ca.gov. At this site you will also find cultivation regulations, as well as manufacturing regulations for medical cannabis.

Part of today’s announcement includes the news of four public hearings for the purpose of public comment on the proposed medical licensing regulations. The Bureau encourages all interested stakeholders to review the proposed regulations and come to a hearing near you to provide feedback. Hearing dates and locations are as follows:

June 1, 2017
10:00 a.m. – 1:00 p.m.
Adorni Center
1011 Waterfront Drive, Eureka, CA 95501

June 8, 2017
10:00 a.m. – 1:00 p.m.
Junipero Serra Building
320 W. Fourth Street, Los Angeles, CA 90013

June 9, 2017
10:00 a.m. – 1:00 p.m.
Department of Consumer Affairs, Hearing Room, S-102
1625 North Market Boulevard, Sacramento, CA  95834

June 13, 2017
1:00 p.m. – 4:00 p.m.
King Library, Second Floor
150 E. San Fernando Street, San Jose, CA 95112

Those who wish to provide feedback and are unable to attend one of the four listed sessions above, can get involved in the regulatory process by following the steps outlined here – http://www.bmcr.ca.gov/about_us/documents/17-065_public_comment.pdf.

There is currently budget trailer bill language designed to align the Medical Cannabis Safety and Regulation Act with Proposition 64, the Adult Use of Marijuana Act. If that bill passes, the bureau will withdraw these proposed regulations and propose a new set of regulations consistent with changes in the law.

However, public comments on the regulations published today are still very important.

“Many of the provisions in the licensing regulations published today will carry over to new regulations if the trailer bill passes,” said Chief Ajax. “Public comment now will provide valuable information and guide our efforts when crafting any new regulations.”

Beginning a little more than a year ago, the Bureau kicked off its outreach efforts with nine informational sessions in locations all around the state. Those sessions were followed up last Fall by eight pre-regulatory stakeholder meetings with discussions centering around issues related to general licensing requirements, and specific concepts related to the regulation of medical cannabis dispensaries, distributors and transporters. The feedback from those sessions can be reviewed here – http://www.bmcr.ca.gov/meetings/summaries.shtml.

For additional information about BMCR, or to subscribe to email alerts to hear about updates as they become available, please visit our website – http://www.bmcr.ca.gov/.

In addition, you can now follow the Bureau on social media!

Facebook: https://www.facebook.com/BMCRinfo/
Twitter: https://twitter.com/BmcrInfo

Advertisements


Leave a comment

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland

Could Switzerland Become the First European Country to Legally Regulate Cannabis?

Nine years after a Swiss referendum failed to gain public approval for cannabis legalisation, a campaign group has reignited the movement for reform.

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland. The objectives of the initiative, Legalize It describes, are three-fold: to allow adults the “freedom and right to consume cannabis”, to prevent those who seek cannabis from having to purchase from the “black market”, and to ensure increased investment into drug use prevention, related research, and social security. The funds for such investment, the group says, will be acquired from the taxation of cannabis sales, and savings on law enforcement expenditure.

The campaign comes in the form of a federal popular initiative, a legislative instrument by which Swiss citizens can suggest changes in the law. If the proposal garners 100,000 valid signatures from Swiss citizens, it will be put forward for debate by the Federal Council, the country’s highest executive authority, and the Federal Assembly, the highest legislative authority.

The Federal Palace of Switzerland. Source: Wikimedia Commons

The cultivation, sale, and use of cannabis are outlawed in Switzerland in almost all cases, however punishment for minor possession is relatively light. Under the current law, an adult found to be in possession of up to 10 grams of cannabis will be fined 100 Swiss francs (£78), and will not be criminally prosecuted. In 2015, there were a total of 18,366 such fines across Switzerland.

Around three percent of adult Swiss residents use cannabis monthly, and almost 40 per cent of adults claim to have used it at least once in their life, according to Addiction Monitoring in Switzerland.

An attempt to legally regulate cannabis was resoundingly opposed by the public in a 2008 referendum, in which 63 per cent of voters opposed the measure. However, the public’s view on the subject has changed over the past decade, according to Nino Forrer, spokesperson for Legalise It.

“Many other countries have legalised or decriminalised cannabis in some form since 2008 and the results are good […] Based on this new data, the Swiss people will see more benefits than harms in legalising cannabis, I’m sure”, Forrer told TalkingDrugs.

“There has not been a massive rise in cannabis consumption among the youth [in places that have legalised cannabis], no surge in traffic accidents, no massive increased health costs. Instead, many jurisdictions have put the extra money from cannabis taxes into public healthcare, infrastructure, and schools in order to improve the standard of living for their people.”

A legal cannabis crow in Colorado. Source: Brett Levin

For example, in 2016, the US state of Colorado collected over $150 million in cannabis sale taxes, of which around $50 million was directed to school projects. Similarly, Legalize Itclaims that taxing the drug could raise 100 million Swiss francs (£78 million) each year, based on their estimates of consumption rates.

Forrer believes that the success of foreign initiatives, such as that in Colorado, may be enough for the Swiss authorities and public to support Legalize It’s new campaign – but only if the message can be effectively be delivered.

“We have had very good responses so far! Many people in Switzerland were waiting for this initiative, so they are very happy that we have started it”, Forrer told us.

“Now, we will try to inform the public as much as possible in order to gather a strong activist base all over the country. Mass media affects our perception of cannabis to a large extent, so good press is needed in order to win over the minds of Swiss people”.

If this initiative proves successful, Switzerland could become the first country in Europe to introduce a legally regulated cannabis market.

Avinash Tharoor is the Editor of TalkingDrugs. He tweets at @AvinashTharoor


Leave a comment

20,000 German pharmacies; supply 3.6 million people daily and provide 150,000 jobs.

http://www.abda.de/newsletter-root/pressemitteilungen/abda-dav-vorsitzender-becker-erste-verbesserungen-fuer-patienten-ernste-herausforderungen-fuer-apotheken/

The laws recently decided to strengthen the medicines and technical aids can improve the care of many patients, but the pharmacies as providers currently facing serious challenges in the regulatory framework. The prohibition on mail for prescription drugs and the strengthening of drug price regulation associated one of the core concerns of pharmacists for the coming legislative term of the Bundestag. This conviction represents the chairman of the German Association of Pharmacists (DAV), Fritz Becker, in his Political Report to the opening of the 54th DAV Economic Forum in Berlin. In the pharmaceutical supply Support Act (AM-VSG) and (HHVG) in medicines and medical aids Supply Act partial success, although had been made, so Becker, but the good supply of medicines in itself is now at risk.

“That finally got the compensation will be adjusted for recipes requiring documentation and drugs, represents a recognition of our pharmaceutical services represent,” says Becker. It also’m him that it no longer intended to give exclusive contracts of insurance in the cytostatic supply. “The free Pharmacies choice – even with cytostatic drugs – is not Bookseller, but practiced patient and consumer protection.” For vaccines he was DAV-Chairman welcomed that the aids tenders now “confident that the delivery problems will fall by the tendering ban.” must take into account quality criteria and additional payments would be monitored more closely. “My fear is that not much will change for the insured in practice. Therefore, we must continue to be vigilant. Just small pharmacies “In addition, excessive documentation requirements could” to waive the provision of aids move “.

Looking at the regulatory and economic uncertainties and imponderables for pharmacies in the outgoing and next legislature Becker calls his colleagues to take decisive action on: “The year of the federal election is ready hold significant challenges for us has to face our profession and will provide – ! with confidence, unity and dedication “The DAV-chairman continued:” Let us continue to fight together for an excellent network of 20,000 pharmacies, which supplies daily 3.6 million people, produces 250,000 messenger services and provides 150,000 jobs. ”

 

 


Leave a comment

German researchers seek 25,000 marijuana users for study

http://www.ibtimes.co.uk/pot-smokers-wanted-german-researchers-seek-25000-marijuana-users-study-1618629

German researchers are hoping to get government backing for a new study that would see the recruitment of 25,000 recreational marijuana smokers.

The Research Initiative on Cannabis Consumption are seeking government approval to analyse the cannabis users in order to understand the effects of the drug after several years of use.

Their application is aimed at conducting a “Scientific Study on Cannabis Sequences for Mentally Healthy Adult Consumers” they say.

Germany legalised marijuana for medicinal purposes earlier in 2017 with new powers given to doctors to prescribe the drug to seriously ill patients at their discretion.

This, researchers say, paves the way for a new study analysing the longer-term effects of the drug.

Cannabis for recreational use is still illegal, but that hasn’t stopped 2,000 people already signing up for the study, say the researchers.

The group announced plans to begin the study in November 2016 saying it wanted to analyse the mental effects on those addicted to the drug.

“In Germany several million people regularly get high on cannabis,” wrote lawyer and chief executive of the project Marko Dörre in a statement released after the plans were submitted.

“It is time that science becomes more engaged with recreational use.”

Marijuana
German researchers are hunting for 25,000 cannabis smokers for a new study.Reuters/John Vizcaino

As part of the study, those selected would be permitted to pick up 30 grams of pharmaceutical cannabis, usually reserved for medical patients, on a monthly basis.

Researchers are prohibiting anyone under 18, first-time marijuana smokers, as well as candidates with high-risk of addiction or psychiatric problems, from taking part in the study.

Before the new act on the Amendment of Narcotics Regulations passed earlier this year, only around 1,000 people with serious medical conditions were permitted to use cannabis.

“With the law implemented in March changing controlled substance regulations, the German parliament took on a new risk assessment of cannabis,” said Dörre.

“The new assessment will also benefit science.”

The BfArM declined to comment to Tagesspiegel as to whether it had in fact received the application or the chances of it being approved.


Leave a comment

The German government finally passed its legalization framework for medical cannabis consumption in March 2017. The country’s market is expected to record modest growth with its high 82 million population and a policy that allows prescriptions to be paid through health insurance plans, …MOTLEY FOOL article

Which Top Marijuana Company Will Capture Germany?

The German government finally passed its legalization framework for medical cannabis consumption in March 2017. The country’s market is expected to record modest growth with its high 82 million population and a policy that allows prescriptions to be paid through health insurance plans, thus potentially encouraging patients to explore medical cannabis health benefits.

Local marijuana producers with vast experience in mass growing of high quality product and hungry to capture the lucrative €12 – €15 a gram (roughly C$17 – C$21.75 per gram) German medical cannabis market, have been taking positions in growing their international business portfolios.

Some of the top local growers have already established footprints in Germany, but which among the local players is likely to gain significant traction in the new market?

Canopy Growth Corp

The local market leader, Canopy Growth Corp. (TSX:WEED) has already made a significant investment in Germany. The company acquired MedCann GmbH Pharma & Nutraceuticals (MedCann) back in November 2016. MedCann, a distributor, has successfully placed Canopy’s Tweed branded cannabis strains into German pharmacies.

The German distribution model strictly  confines cannabis sales to the pharmacy distribution model and no direct sales shall be allowed. Since all sales shall take the wholesale distribution channel, Canopy is already at a first mover advantage in this market.

Canopy has indicated that it is interested in producing cannabis locally in Germany with the expansion of the local program. With Germany expecting to launch a domestic cannabis cultivation initiative by 2019, Canopy is likely to try broadening its expansion program in the country.

Aphria Inc.

Aphria Inc. (TSX:APH) has recently announced an international expansion program that is currently focused on the United States market, and has committed $25 million to an investment in Florida. Its not yet clear whether it intends to make serious investments in the new German market, but it has been eyeing this market for some time.

Although it had not yet made any formal engagements in Germany by January 2017, the CEO Vic Neufeld, in an interview with the Midas Letter openly stated that Germany has been very much on Aphria’s radar, and the company once engaged in dialogue with two different organisations pertaining the German market.

However, Aphria has been very cautious in their Canada and U.S. expansion programs so far. It seems the company has a slow-but-sure approach to doing business as its Canadian operations have shown, so I do not expect an overly vigorous and aggressive German expansion program from them.

Aurora Cannabis Inc.

One of the fastest growing and most aggressive marijuana producers, Aurora Cannabis Inc.(TSXV:ACB), has recently announced a $75 million convertible debenture offering which is likely to close on April 26, 2017, with a clear intent of using the funds to “aggressively pursue international expansion opportunities,” says CEO Terry Booth.

The company believes the $185 million cash position gives them the strongest cash balance “in the global cannabis sector,” and Aurora wants to play a leading role “in multiple emerging global cannabis markets.” 

Its most likely Aurora may attempt a German expansion route. Given the company’s growth style, it goes big on ventures and seeks aggressive expansion. These traits have seen it emerging to become a serious top contender in the Canadian marijuana space in a very short time.

Most noteworthy, Aurora is already listed on the Frankfurt Stock Exchange in Germany and raising expansion funds locally may be relatively easier.

Investor takeaway.

Its not yet clear who among these top marijuana companies may become a serious investor in Germany, but Canopy already commands a serious lead.

There are other serious Canadian contenders to the German market, like the soon-to-be-listed Maricann Group Inc, which is already trying to acquire an 800,000 square foot facility and likely seeking a cultivation license in Germany, and  CanniMed Therapeutics and the Cronos Group who already have distribution relationships in the European country.

However, there will be competition from Netherlands entities too, but the market may not be that big enough to support massive investment as yet. Canadian growers who manage to capture the infant German market may be rewarded though, as they will gain first mover advantages into the opening European market.

According to Google, “Marijuana” has been a more popular search term in Canada lately than our very own Justin Trudeau. And, not surprisingly, marijuana stocks have been the most popular topic for Motley Fool Canada readers for some time…and for good reason! However, not all “pot stocks” are created equal. That’s why we’ve created our premium report “Motley Fool Canada: 3 Marijuana Stock Tips for Investors Today.” Discover how you can gain access to the 3 stocks we believe investors should focus on in this premium Stock Advisor Canada report by clicking here now!


Leave a comment

https://cenedella.de/ * Philip J. Cenedella IV * International Cannabis Consultant * Germany, Europe, USA and Canada markets * Medical Marijuana Patient Advocate since 1977 * Assist with Business Development, Licensing, Partnerships, and Strategic Direction.

Philip J. Cenedella IV

Bio

https://cenedella.de/
Philip J. Cenedella IV
International Cannabis Consultant
Medical Marijuana Patient Advocate since 1977.

First and foremost, Phil is a patient advocate for 4 decades having grown up in New York during the Rockefeller Drug Law years, then establishing himself in San Diego during the push for legalization there in the’ 90s.  Now he is situated in Germany during its historic transition into the leadership role of the European Cannabis industry.

Phil is uniquely qualified to help you establish your international business strategy having served as a Founding Board Member of the World Trade Center San Diego, a Lead Consultant for Deutsche Telekom, The California Trade and Investment Office, Deutsche Bank, IBM, San Diego Economic Development Board and many other entities.  He puts his years of business development, sales and distribution expertise to work for you in a highly professional, ethical and effective manner.

40 Years Experience:
Phil was born in Buffalo on the shores of the US/Canadian border, spent most of his life in San Diego overlooking the US/Mexico border, and now is living in Europe with its open borders and the opening of its legal Cannabis industry.

As a C-level business development executive in the technology and construction sectors, and a Founding Board of Director for the World Trade Center San Diego and San Diego Software Council, Phil has facilitated and closed sales and strategic partnerships worldwide.

Phil has also been Lead Consultant for the California Trade and Investment Office in Germany and catalyst for the CAL-IT Investment Forum in London.

He has served as a consultant for IBM, George Clinton, Deutsche Telekom, iSeeTV,  San Diego Convention Center, FINDLAW, Chaparral Computers and Networks, San Diego Economic Development Corporation, Deutsche Bank and many others in the Cannabis space (to remain confidential).

Phil is a USA citizen with an EU Work/Residence Permit.  He has exactly 40 years of firsthand knowledge of all aspects of our Industry and is a C-level International business development specialist who is highly professional yet very easy to work with.  He provides your firm with Strategic guidance and the ability to help you to increase your sales channels, distribution networks, and strategic partnerships.

Education:
1984, University of Dayton B.A. Psychology, Music minor-emphasis

Skill Level:
Sales 98%
Business Development 98%
International  trade 98%
Cannabis Industry 420%

Testimonials

 Who is Phil:
“Phil is an absolute professional. Flexible, hardworking and driven. His results were great and we highly recommend his services.” – BLF, NYC

“Phil has boundless enthusiasm and always applies 100% effort to all he does. Phil researched the US market for…. The USA became our best market by far, and I know that we would never have broken into that extremely tough market without Phil. His combination of broad based business knowledge, willingness to learn, team spirit and superb networking skills is very rare and extremely valuable. Always positive, he was a joy to work with. I thoroughly recommend him.” – GRB, UK

“Phil Cenedella has been my contact for several years and I have found him to be the consummate professional. He will always promptly return a call or provide me an answer to an inquiry. He is always “on-it” and truly treats a client as if they were part of his extended family. It’s very rare these days to find someone as dedicated to his business and his clients as Phil. Phil has all the characteristics of what I look for when I have occasion to be expanding my staff. He is honest to a fault, dedicated, sincere and is the paramount reason for my firm’s continuing…….” – DF ,USA

“Phil is the most personable, genuine, charismatic and effective business development manager I have had the pleasure to work with. He instills trust and confidence!”- JFL, EU

“Phil is family.” – George Clinton
Volunteer Positions:    Founder, Dayton and La Jolla Human Trafficking Accords, Founder, St. Vincent de Paul Christmas Caroling and Limo Party, Volunteer, Americans for Safe Access, Advisor, City of Hope – Dubai  Key accomplishments:  Assisted with the freeing from prison a child victim of human trafficking serving life without parole, initiated Goldman Sachs’ divestment of a human-trafficking related publication, assisted advocates on the frontlines in Dubai, Ohio, California and elsewhere.


Leave a comment

CANADA: ‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

Adrian Wyld/ The Canadian Press”We didn’t want all those people excluded automatically from the possibility of participating in some way,” Anne McLellan, now a senior advisor at Bennett Jones LLP, said. Twitter Google+ LinkedIn Email Typo? MoreBlack market marijuana growers should be included in the legal market as they can provide valuable expertise as it evolves, Anne McLellan, chair of the federal government’s task force on legalization, said Monday.McLellan said the Task Force on Cannabis Legalization and Regulation, whose recommendations were broadly adopted in the government’s proposed Cannabis Act, concluded that previous criminal convictions during marijuana’s century of prohibition “shouldn’t be an automatic bar to them coming into the legal system.”“We didn’t want all those people excluded automatically from the possibility of participating in some way,” McLellan, now a senior advisor at Bennett Jones LLP, said in an interview with the Financial Post on the sidelines of a conference on cannabis regulation organized by the Ryerson University in Toronto.The task force’s November report called on the federal government to set up a system that allows various-sized producers to participate, including independent and craft growers.“There are lots of people who are producing now illegally — we talk about artisinal and craft producers — we want a diversity of producers,” McLellan said.“There’s an awful lot of expertise that’s outside the legal system right now and you wouldn’t want to lose all that.”RelatedMarketing restrictions to help small marijuana brands compete against deep-pocketed players: panel‘Turning green into green’: Payment startup aims to capitalize on banking void for marijuana companiesSome Canadian pot activists, including Marc and Jodie Emery, have expressed their disappointment that the draft legislation sets up a system that favours “big marijuana” because the federal government will strictly regulate and license who can produce the plant for sale. Under the current medical marijuana regime, Ottawa has handed out some 40 licences to produce, a small fraction of the number of applicants. However, McLellan points out that producing, manufacturing or selling pot are not the only economic opportunities in the coming multi-billion dollar legal marijuana market.“There are other ways for people to be involved in this industry. People focus on production or manufacturing, retail, and that’s all important, but that’s only the most visible part,” she said.“A lot is going to happen here and there are so many access points for people to be involved.”There are also a plethora of weed-related businesses —from fertilizers to security services to payment processors — carving niches in the space ahead of legalization expected in July 2018.Jodie and Marc Emery, owners of Cannabis Culture, at their store on Church Street in Toronto. They are quickly expanding their empire of dispensaries across Canada and are determined to do so regardless of whether the coming recreational market legalizes dispensaries like theirs. ” data-medium-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=300″ data-large-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=620″ class=”size-large wp-image-734308″ alt=”Tyler Anderson/National Post” src=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389″ width=”620″ height=”389″ srcset=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389 620w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=1240&quality=60&strip=all&h=778 1240w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=140&quality=60&strip=all&h=88 140w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=300&quality=60&strip=all&h=188 300w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg” style=”max-width:100%;” />